Javitt Jonathan C 4
4 · NRX Pharmaceuticals, Inc. · Filed Dec 18, 2024
Insider Transaction Report
Form 4
Javitt Jonathan C
DirectorChairman and Chief Scientist10% Owner
Transactions
- Purchase
Common Stock
2024-12-17$1.17/sh+40,000$46,800→ 84,634 total
Holdings
- 30,000(indirect: By the Jonathan Javitt Donor Advised Fund)
Common Stock
- 1,260,000(indirect: By Trust)
Common Stock
- 142,200(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]Held by the Jonathan Javitt Living Trust of which the reporting person is the trustee.
- [F2]Held by the Javitt 2012 Irrevocable Dynasty Trust of which the reporting person is the grantor of such trust. The reporting person is not a trustee or beneficiary of the Trust, and no beneficiary of the Trust resides in the reporting person's household. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- [F3]Held by the Jonathan Javitt Donor Advised Fund of which the reporting person is the primary advisor of such fund.